- Companies
- MedAlliance
MedAlliance Acquisition, Valuation, Funding & Investors
MedAlliance was acquired by Cordis for $1.1B in October 2022.
MedAlliance acquisition price
$1.1B
Acquired by Cordis · Oct 2022
Cumulative funding MedAlliance raised
$50M
across 1 funding round
Key investors in MedAlliance
CITIC Capital Holdings
Trustar Capital
About MedAlliance
MedAlliance is a Geneva-headquartered medical technology company developing paclitaxel-coated drug-eluting balloons for coronary and peripheral artery disease treatment. Its SELUTION platform uses a biodegradable polymer for sustained drug release, with CE Mark approval in Europe and ongoing U.S. FDA trials, targeting in-stent restenosis and below-the-knee lesions.
Founded
2008
HQ
Website
Status
Acquired
Customer focus
B2B
Revenue model
Product sales
Valuation
$1.1B (acquired Oct 2022)
Sectors
MedAlliance Acquisition
MedAlliance was acquired by Cordis for $1.1B on 17 October 2022.
Before the acquisition MedAlliance had raised $50M across 1 funding round.
| Acquirer | Date | Type | Price |
|---|---|---|---|
| 17 Oct 2022 | Strategic M&A | $1.1B |
MedAlliance Funding History
MedAlliance has raised a total of $50M across 1 funding round.
MedAlliance funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2021 | Undisclosed stage | CITIC Capital Holdings (lead); Trustar Capital | $50M | MedAlliance is a Swiss medtech company headquartered in Nyon (canton of Vaud) dedicated to developing innovative drug-eluting balloons (DEBs) for patients with life-threatening coronary and peripheral arterial disease. The company's flagship product, SELUTION SLR, is a sirolimus-eluting balloon that provides controlled sustained release of a limus drug with similar elution time to drug-eluting stents while leaving nothing behind. The technology combines the proven safety and efficacy of sirolimus with microreservoirs made of biodegradable polymer as drug delivery systems and a proprietary lipid technology that binds microreservoirs to the balloon surface. In March 2021, MedAlliance raised over USD 50 million in equity funding from Trustar Capital, the private equity affiliate of CITIC Capital Holdings Limited. This financing was designated to fund commercialization of SELUTION SLR and support global clinical programs. MedAlliance had achieved a significant regulatory milestone as the first drug-eluting balloon company in the world to receive US FDA Breakthrough Device Designation Status for a sirolimus DEB, with SELUTION SLR recently awarded breakthrough status for treatment of atherosclerotic lesions in native coronary arteries. The investment reflects confidence in MedAlliance's market position and technology differentiation in the interventional cardiology space. |
Who has invested in MedAlliance?
2 investors have backed MedAlliance across its funding rounds, including CITIC Capital Holdings and Trustar Capital.
Lead investors include CITIC Capital Holdings.
MedAlliance Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 2 MedAlliance investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by MedAlliance
MedAlliance has acquired 1 company to date.
Last acquisition by MedAlliance was on February 3rd 2022. MedAlliance acquired MDK Medical for undisclosed valuation.
Latest Acquisitions by MedAlliance
| Description | MDK Medical is a Tokyo-based specialist in vascular medical devices, focusing on guidewires, catheters, and sheaths for endovascular procedures. The company supplies products for peripheral artery disease treatments and coronary interventions, holding approvals from Japan's Pharmaceuticals and Medical Devices Agency. MDK Medical partners with global firms like Terumo and Boston Scientific for distribution in Asia-Pacific markets, emphasizing high-performance hydrophilic coatings and torque control in its lineup. |
| HQ Country | |
| HQ City | Tokyo |
| Deal Date | 3 Feb 2022 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all MedAlliance acquisitions and their M&A valuation multiples. Start Free Trial | |
MedAlliance Competitors
MedAlliance competitors include listed companies like SEEGENE and Obsidian Therapeutics, and private ones like Huihe Healthcare, Scivita Medical Technology, FibroGen and Rapid Medical.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $345M | $85M | $1.1B | 2.1x | ||
| Private | - | - | $1.1B | - | ||
| Publicly listed | - | ($104M) | $1.1B | - | ||
| Private | - | - | $1.1B | - | ||
| Private | $108M | - | $1.2B | 11.3x | ||
| Private | - | - | $1.3B | - |
MedAlliance Public Comps
MedAlliance is no longer listed, but its public comps include Beta Bionics, SEEGENE, PROCEPT BioRobotics, Artivion, PHC Holdings, Avanos Medical, Integra Lifesciences, Shinva, SonoScape and MicroPort EP.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $100M | ($81M) | 9.5x | 8.0x | (11.7x) | (14.1x) | |||
| $345M | $85M | 2.3x | 2.1x | 9.2x | 7.7x | |||
| $308M | ($98M) | 3.1x | 2.6x | (9.9x) | (25.1x) | |||
| $441M | $63M | 3.4x | 3.1x | 23.7x | 16.0x | |||
| $2.3B | $320M | 1.0x | 1.0x | 7.2x | 6.5x | |||
| $701M | $87M | 1.8x | 1.8x | 14.3x | 14.3x | |||
| $1.6B | ($344M) | 1.8x | 1.8x | (8.6x) | 8.9x | |||
| $1.5B | $126M | 0.6x | 0.6x | 6.7x | 6.7x | |||
This data is available for Pro users. Sign up to see all MedAlliance competitors and their valuation data. Start Free Trial | ||||||||
Common questions about MedAlliance
| When was MedAlliance founded? | MedAlliance was founded in 2008. |
| Where is MedAlliance headquartered? | MedAlliance is headquartered in Nyon, Switzerland. |
| Is MedAlliance publicly listed? | No, MedAlliance was acquired by Cordis in October 2022. |
| Who acquired MedAlliance? | MedAlliance was acquired by Cordis in October 2022. |
| How much was MedAlliance acquired for? | MedAlliance was acquired for $1.1B in October 2022. |
| How much funding has MedAlliance raised? | MedAlliance has raised $50M across 1 funding round. |
| What was MedAlliance's last funding round? | MedAlliance's last funding round was a $50M undisclosed-stage round in March 2021, led by CITIC Capital Holdings. |
| Who are MedAlliance's investors? | MedAlliance's investors include Trustar Capital and CITIC Capital Holdings. |
| Which companies are comparable to MedAlliance? | Companies comparable to MedAlliance include SEEGENE, Huihe Healthcare, Obsidian Therapeutics, Scivita Medical Technology, FibroGen and Rapid Medical. |
| How many companies has MedAlliance acquired? | MedAlliance has acquired 1 company, including MDK Medical. |
See companies similar to MedAlliance
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




